Professor Simon Dixon BSc (Southampton), MSc (York), PhD (Sheffield)
Professor of Health Economics
The University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Direct telephone: (+44) (0)114 222 0724
General office fax: (+44) (0)114 222 0749
My work at ScHARR has concentrated around undertaking and developing methods for economic evaluations alongside controlled trials. Whilst the main focus of this work has been pre-hospital and emergency care, I have undertaken evaluations in numerous other areas. A separate stream of work is examining the measurement and valuation of health care benefits. This is focusing on alternatives to, and extensions of, the standard QALY model.
- Public preferences for public health (link to project page under 'Projects').
- Methods of HTA and reimbursement systems
- Measurement and valuation of health care benefits.
- Economic evaluation.
My teaching is concentrated around the methods of economic evaluation which I teaching in various formats on the MSc Health Economics and Decision Modelling, MSc Economics and Health Economics, MSc International Health Technology Assessment, Pricing and Reimbursement and the MBChB.
I am the module coordinator for the Economic Evaluation modules on MSc International Health Technology Assessment, Pricing and Reimbursement.
I am interested in supervising Research Students wishing to develop the methods of economic evaluation and benefit valuation. I am particularly interested in empirical ethics and a more empirically based QALY approach, including the role of sequences and process utility.
I currently supervise, or sit on the supervisory panel for three students; Victoria Brennan, Kinga Lowrie and Sabine Grimm. Their topics relate to the evaluation of an electronic patient questionnaire, evaluation of telehealth and the valuation of innovation in non-pharmaceutical technologies.
I am currently supervising the following postgraduate research students:
Genevieve David, who is examining the role of public preferences in alcohol licensing decision making in English local authorities.
Yingpeng Qui, who is exploring methods to supporting the development of National List of Appropriate Health Technology in China.
Naomi Gibbs who is exploring the health economic and equity impacts of alcohol pricing policies in South Africa.
Abu Alshreef who is a NIHR Doctoral Research Fellow, looking at the development of a methodological framework to account for the impact of non-adherence on the cost-effectiveness of prescribed chronic medications.
Chu Chang Ku is researching healthcare seeking behaviour as a link between tuberculosis and socioeconomic factors using hybrid modelling.
- Honorary Professor in the Priority Cost Effective Lessons for Systems Strengethening (PRICELESS), School of Public Health, University of Witwatersrand.
- External Examiner at the University of York for the PG Cert and PG Dip Health Economics for Health Care Professionals; MSc Economic Evaluation for Health Technology Assessment.
- Academic Committee of the Center for Healthcare Big Data of Tsinghua Center for Statistical Science.
- Advisory Board for HERU, University of Aberdeen
- Salivary Cortisone as an Adrenal Insufficiency Test (SCAIT)
- Take home naloxone In Multicentre Emergency setting feasibility trial (TIME)
- Increasing uptake of effective self-management education programmes for type 2 diabetes in multi-ethnic primary care settings
- NIHR Global Health Research Group on Preterm Birth Prevention and Management (PRIME)
- Development of customised non-invasive ventilation interfaces for children for whom current commercial masks are unavailable or unsuitable to improve ventilation therapies and reduce complications.
- Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE); a superiority randomised clinical trial to evaluate the effectiveness and cost effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms
- Whyte S, Dixon S, Faria R, Walker S, Palmer S, Sculpher M & Radford S (2016) Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?. Value in Health, 19(2), 138-144. View this article in WRRO
- Rowen D, Dixon S, Hernández-Alava M & Mukuria C (2016) Estimating informal care inputs associated with EQ-5D for use in economic evaluation. The European Journal of Health Economics, 17(6), 733-744. View this article in WRRO
- Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Dixon S, Maguire C, Cantrill H, Alexander J, Lenney W , McNamara P et al (2015) Saline in acute bronchiolitis RCT and economic evaluation: hypertonic saline in acute bronchiolitis - randomised controlled trial and systematic review.. Health Technology Assessment, 19(66), 1-130. View this article in WRRO
- Thokala P, Dixon S & Jahn B (2015) Resource Modelling: The Missing Piece of the HTA Jigsaw?. PharmacoEconomics, 33(3), 193-203. View this article in WRRO
- Tosh J, Dixon S, Carter A, Daley A, Petty J, Roalfe A, Sharrack B & Saxton JM (2014) Cost effectiveness of a pragmatic exercise intervention (EXIMS) for people with multiple sclerosis: economic evaluation of a randomised controlled trial.. Mult Scler, 20(8), 1123-1130.
- Shackley P & Dixon S (2013) The random card sort method and respondent certainty in contingent valuation: An exploratory investigation of range bias. Health Economics (United Kingdom).
- Brennan VK & Dixon S (2013) Incorporating process utility into quality adjusted life years: a systematic review of empirical studies.. Pharmacoeconomics, 31(8), 677-691.
- Dixon S, Shackley P, Bonham J & Ibbotson R (2012) Putting a value on the avoidance of false positive results when screening for inherited metabolic disease in the newborn.. J Inherit Metab Dis, 35(1), 169-176.
- Dixon S, Poole CD, Odeyemi I, Retsa P, Chambers C & Currie CJ (2011) Deriving health state utilities for the numerical pain rating scale.. Health Qual Life Outcomes, 9, 96. View this article in WRRO
- Gillett M, Dallosso HM, Dixon S, Brennan A, Carey ME, Campbell MJ, Heller S, Khunti K, Skinner TC & Davies MJ (2010) Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis.. BMJ, 341, c4093.